Occupational exposure to cytostatic drugs, including dacarbazine [5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide – DTIC], has long represented a significant occupational safety issue in the healthcare sector due to their mutagenic and potentially carcinogenic properties. In Poland, according to Central Register of Exposure Data on Chemical Substances, the total number of workers occupationally exposed ryto DTIC in 2024 was 6319. The aim of this study is to review and analyze available experimental data on the carcinogenic properties of DTIC, obtained mainly from animal studies, in the context of assessing potential health risks for occupationally exposed individuals. A literature review was conducted of Polish- and English-language publications up to December 2025, using Scopus, PubMed, Web of Science, and Google Scholar databases. Experimental animal studies, reports from international institutions including International Agency for Research on Cancer and the European Commission, as well as medicinal product characteristics, were analyzed. Dacarbazine demonstrates genotoxic properties confirmed in both in vitro and in vivo animal studies. In selected biomonitoring studies of genotoxic effects in workers occupationally exposed to cytostatics, changes suggesting DNA damage have been reported; however, the available data are limited. Animal studies indicate carcinogenic effects involving multiple organs, including the lungs, mammary gland, lymphatic system, and central nervous system, as well as transplacental effects. Quantitative risk assessment models (e.g., Dutch Expert Committee on Occupational Standards), based on toxicological extrapolation, indicate a relationship between exposure level and estimated model-based cancer risk (4 × 10^–⁵ at an exposure concentration of 0.9 μg/m^³). Dacarbazine demonstrates genotoxic and carcinogenic potential in experimental studies. Due to the absence of a clear threshold for genotoxic effects, potential health risks associated with occupational exposure cannot be excluded. The implementation of collective and personal protective measures, including closed-system drug transfer devices and environmental monitoring of workplace contamination, is essential. Med Pr Work Health Saf. 2026;77(6)